title: In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells.
abstract: Chronic myeloid leukemia (CML), also recognized as chronic myelogenous leukemia, is initiated in some types of blood-forming cells of the bone marrow. The therapeutic approach to CML is usually chemotherapy; however, severe side effects and complications are major problems in the clinical research. Thus, recent efforts have focused on the search for compounds affecting apoptosis in this type of cancer.
  
  
  
  In this study, in vitro anticancer activity of two compounds (A and B) consisting of a hydrazide backbone with nitro-thiophen and furan substituents was assessed against K562 cell line displaying certain levels of sensitivity to pro-apoptotic compounds.
  
  
  
  The anticancer activity was assessed using MTT assay, flowcytometry, annexin-V and Western blot analysis.
  
  
  
  Compounds A and B were both active and revealed a remarkable in vitro cytotoxic effect showing IC50 values of 0.09 and 0.07 μM, respectively, after 72 h of treatment. A significant increase in annexin-V/PI staining, sub-G1 population and Bax/Bcl-2 ratio revealed the apoptotic cell death of compounds A- and B-treated K562 cells.
  
  
  
  The results presented here could be used as a first step for the development of powerful chemotherapeutic agents to treat leukemia.
authors.forename: Shahrzad
authors.initials: S
authors.lastname: Tavakolfar
authors.forename: Elham
authors.initials: E
authors.lastname: Mousavi
authors.forename: Ali
authors.initials: A
authors.lastname: Almasirad
authors.forename: Amir
authors.initials: A
authors.lastname: Amanzadeh
authors.forename: Seyyed Mohamamd
authors.initials: SM
authors.lastname: Atyabi
authors.forename: Parichehr
authors.initials: P
authors.lastname: Yaghamii
authors.forename: Somayeh
authors.initials: S
authors.lastname: Samiee-Sadr
authors.affiliation: Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, P.O. Box 13164, Iran. salimimona@pasteur.ac.ir.
authors.forename: Mona
authors.initials: M
authors.lastname: Salimi
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D006834:Hydrazines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D015394:Molecular Structure; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D006834:Hydrazines